COVID-19 Impact on Neuropsychiatric Disorders

In this sample, we used a semi-structured interview to get information on COVID-19 symptoms and to assess the impact of the COVID-19 pandemic on the disease perception. A senior psychiatrist, together with a senior neurologist, carried out the semi-structured interview. The final assessment was based on information from caregivers and from any medical documentation, too. The interview consisted of: (a) socio-demographic and clinical data. In particular, we collected the age at which the individual first experiences psychiatric symptoms, disease duration, the phenomenology of the FMD, neuropsychiatric current pharmacological treatment, psychotherapy, physical therapy, botulinum toxin therapy and disability measures; (b) COVID-19-related questions, mainly focused on its effect on the disease burden, in particular on neurological symptoms, emergency neurological assistance, pharmacological treatment break-off or physiotherapy withdrawal. All data collected were entered in preprinted medical records.